Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial
Open accessAbstract
In the present randomized, controlled, double-blind trial (12 wk treatment plus double-blind extension for 12 wk), 25–50 mg/d agomelatine (n = 164) and 10–20 mg/d escitalopram (n = 160) were compared for short- and long-term efficacy, subjective sleep and tolerability. The effects of these drugs on emotional experiences were also compared in patients having completed the Oxford Questionnaire on the Emotional Side-Effects of Antidepressants (agomelatine: n = 25; escitalopram: n = 20). Agomelatine and escitalopram similarly improved depressive symptoms, with clinically relevant score changes over 12 and 24 wk and notable percentage of remitters (week 12: 60.9 and 54.4%; week 24: 69.6 and 63.1% respectively). Over the 12 and 24-wk treatment periods, the ‘global satisfaction on sleep’ scores increased in both treatment groups and did not differ between groups. Satisfaction with sleep–wake quality was high in both groups; the ‘wellness feeling on waking’ was more improved with agomelatine than with escitalopram (p = 0.02). In patients with pronounced sleep complaints, quality of sleep and feeling on waking were significantly more improved with agomelatine than with escitalopram (p = 0.016 and p = 0.009, respectively). Emotional blunting was less frequent on agomelatine than on escitalopram. Indeed, 28% of patients on agomelatine vs. 60% on escitalopram felt that their emotions lacked intensity and 16% of patients on agomelatine vs. 53% on escitalopram felt that things that they cared about before illness did not seem important any more (p = 0.024). The tolerability profile of agomelatine was found to be superior to that of escitalopram and the incidence of patients with at least one emergent adverse event leading to treatment discontinuation was lower in the agomelatine group than in the escitalopram group (5.5 vs. 10.6%). The findings suggest that agomelatine displays additional long-term clinical benefits on sleep–wake quality and emotional experiences over escitalopram in the management of depression.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Emotional blunting is less frequent in patients taking agomelatine than escitalopram and less severe when medication is switched from SSRIs/SNRIs to vortioxetine.
“In more recent studies, emotional blunting has been found to be less frequent in patients taking agomelatine than escitalopram (SSRI) and less severe when medication was switched from SSRIs/SNRIs to vortioxetine (32, 39).”
From Emotional Blunting in Patients With Major Depressive Disorder: A Brief Non-systematic Review of Current Research (2021) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Lemaître, B. J., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 595 · see citing works
Patel, B. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2008) · CNS Drugs · doi:10.2165/0023210-200923010-00003 · Cited by 466 · see citing works
Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709006011 · Cited by 458 · see citing works
Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study
Price, J., Cole, V., & Goodwin, G. M. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051110 · Cited by 362 · see citing works
Self-citationSleep and circadian rhythms in mood disorders
Armitage, R. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.00968.x · Cited by 344 · see citing works
Olié, J., & Kasper, S. F. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007766 · Cited by 257 · see citing works
Kasper, S. F., Hajak, G., Wulff, K., Hoogendijk, W. J. G., Montejo, A. L., Smeraldi, E., RYBAKOWSKI, J. K., Quera-Salva, M.-A., Wirz‐Justice, A., Picarel-Blanchot, F., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05347blu · Cited by 256 · see citing works
Lemoine, P., & Guilleminault, C. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1112 · Cited by 217 · see citing works
Kennedy, S. H., Rizvi, S. J., Fulton, K., & Rasmussen, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b48c · Cited by 211 · see citing works
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196 · see citing works
Major depressive disorder, sleep EEG and agomelatine: an open-label study
Quera-Salva, M.-A., Vanier, B., Laredo, J., Hartley, S., Chapotot, F., Moulin, C., Lofaso, F., & Guilleminault, C. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007754 · Cited by 170 · see citing works
Agomelatine in the Treatment of Major Depressive Disorder
Kennedy, S. H., & Rizvi, S. J. (2010) · CNS Drugs · doi:10.2165/11534420-000000000-00000 · Cited by 149 · see citing works
Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., & Manber, R. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002870 · Cited by 147 · see citing works
Hindmarch, I. (1975) · PubMed · Cited by 147 · see citing works
Hale, A. S., Corral, R. M., Mencacci, C., Ruiz, J. S., Severo, C. A., & Gentil, V. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833a86aa · Cited by 127 · see citing works
Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse
Iovieno, N., van Nieuwenhuizen, A., Clain, A., Baer, L., & Nierenberg, A. A. (2011) · Depression and Anxiety · doi:10.1002/da.20768 · Cited by 98 · see citing works
Montejo, A. L., Prieto, N., Terleira, A. I., Matias, J., Alonso, S., Paniagua, G., Naval, S., Parra, D., Gabriel, C., Mocaër, E., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108096507 · Cited by 97 · see citing works
Quera-Salva, M.-A., Hajak, G., Philip, P., Montplaisir, J., Gall, S. K.-L., Laredo, J., & Guilleminault, C. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328349b117 · Cited by 90 · see citing works
Impact of the novel antidepressant agomelatine on disturbed sleep–wake cycles in depressed patients
Quera-Salva, M.-A., Lemoine, P., & Guilleminault, C. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1112 · Cited by 86 · see citing works
Colonna, L., Andersen, H. F., & Reines, E. H. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65484 · Cited by 82 · see citing works
Agomelatine facilitates positive versus negative affective processing in healthy volunteer models
Harmer, C. J., de Bodinat, C., Dawson, G. R., Dourish, C. T., Waldenmaier, L., Adams, S., Cowen, P. J., & Goodwin, G. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110376689 · Cited by 77 · see citing works
Self-citationResidual Symptoms in Depression
Menza, M. A., Marín, H., & Opper, R. S. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0504 · Cited by 74 · see citing works
Depression and Sleep Disorders: Clinical Relevance, Economic Burden and Pharmacological Treatment
Brunello, N., Armitage, R., Feinberg, I., Holsboer‐Trachsler, E., Léger, D., Linkowski, P., Mendelson, W. B., Racagni, G., Saletu, B., Sharpley, A. L., et al. (2000) · Neuropsychobiology · doi:10.1159/000026680 · Cited by 65 · see citing works
Clinical Studies on the Efficacy of Agomelatine on Depressive Symptoms
Goodwin, G. M. (2009) · CNS Drugs · doi:10.2165/11318650-000000000-00000 · Cited by 20 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759 · see citing works
Vadnie, C. A., & McClung, C. A. (2017) · Neural Plasticity · doi:10.1155/2017/1504507 · Cited by 199 · see citing works
Cao, B., Zhu, J., Zuckerman, H., Rosenblat, J. D., Brietzke, E., Pan, Z., Subramanieapillai, M., Park, C., Lee, Y., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.002 · Cited by 175 · see citing works
The efficacy of vortioxetine on anhedonia in patients with major depressive disorder
Cao, B., Park, C., Subramaniapillai, M., Lee, Y., Iacobucci, M., Mansur, R. B., Zuckerman, H., Phan, L., & McIntyre, R. S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00017 · Cited by 139 · see citing works
Ma, H., Cai, M., & Wang, H. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.792960 · Cited by 59 · see citing works
2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association
Drager, L. F., Assis, M., Bacelar, A. F. R., Poyares, D. L. R., Conway, S. G., Pires, G. N., de Azevedo, A. P., Carissimi, A., Eckeli, A. L., Pentagna, Á., et al. (2023) · Sleep Science · doi:10.1055/s-0043-1776281 · Cited by 25 · see citing works
Christensen, M. C., Ren, H., & Fagiolini, A. (2022) · Annals of General Psychiatry · doi:10.1186/s12991-022-00391-5 · Cited by 12 · see citing works
- Authors
- Corruble, E., de Bodinat, C., Belaïdi, C., & Goodwin, G. M.
- Affiliations
- Inserm (FR)
- Institut de Recherches Internationales Servier (IRIS), Suresnes Cedex, France
- Institut de Recherches Internationales Servier (France) (FR)
- Warneford Hospital (GB)
- Corresponding author
- Corruble, Emmanuelle
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-01
- Volume
- 16
- Issue
- 10
- Pages
- 2219-2234
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2161185297
- Cited by
- 94
- References
- 25
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 9 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 3 · 2017: 6 · 2016: 8 · 2015: 13 · 2014: 10 · 2013: 2
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Eisai
- Servier
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Keywords
- agomelatine, escitalopram, major depressive disorder, antidepressant efficacy, subjective sleep, emotional blunting, tolerability, treatment discontinuation, sleep quality, remission, melatonin receptor agonists, selective serotonin reuptake inhibitors, adverse events
- MeSH terms
- Acetamides, Adult, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Emotions, Female, Humans, Hypnotics and Sedatives, Male, Middle Aged, Naphthalenes, Surveys and Questionnaires, Sleep, Time Factors, Wakefulness, Citalopram, Treatment Outcome, Patient Satisfaction, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
